MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration
A new study found that combining SSRIs and psilocybin is not only safe, but may be beneficial!
Yesterday, MindMed (MNMD) announced the findings from several ongoing studies conducted in collaboration with UHB Liechti Lab.
In one study, psilocybin was found to be safe to administer with an SSRI antidepressant and did not reduce the psychedelic experience. Two weeks prior to the psilocybin dose, volunteers were give a daily pretreatment of the SSRI escitalopram. As a result, the volunteers experienced reduced anxiety and blood pressure increases that occur with psilocybin administration.
Another study compared the perceptual effects of psilocybin to LSD and revealed that a 20 mg dose of psilocybin is equivalent to 100 mcg of LSD.
The company will continue to analyze the study data and will publish additional findings later this year.